Takeda and Indonesia to build national plasma ecosystem for PDMPs
- The Ministry of Health granted Takeda a plasma fractionation license.
- Takeda will invest up to $30 million in a two-year pilot to establish plasma donation centers and evaluate a national network.
- The first plasma donation center is expected to open in 2027; collected plasma will initially be fractionated within Takeda’s global manufacturing network.
- Takeda will assess feasibility and regulatory requirements for a local PDMP manufacturing facility to serve domestic and international markets.
Overview
Takeda and the Indonesian government announced a multi-year collaboration after the Ministry of Health granted Takeda a plasma fractionation license. The initiative aims to strengthen Indonesia’s plasma ecosystem and expand access to plasma-derived medicinal products (PDMPs) domestically and regionally.
Investment and pilot
Takeda will invest up to 30 million U.S. dollars in a two-year pilot to establish plasma donation centers and test operational models ahead of potential scale-up into a national network. Centers will join Takeda’s BioLife plasma center network and follow international quality and regulatory standards; the first center is expected to open in 2027.
Manufacturing and supply chain
While Takeda assesses feasibility and regulatory requirements for a state-of-the-art local PDMP manufacturing facility, plasma collected in Indonesia will be fractionated within Takeda’s existing global manufacturing network, with a commitment to prioritizing Indonesia’s domestic needs in line with applicable laws and regulations.
Objectives and regional impact
The collaboration targets sustainable collection of high-quality plasma, workforce training, technology transfer and job creation, and seeks to position Indonesia as a regional hub for plasma science and biopharmaceutical manufacturing to address growing global demand for PDMPs and underdiagnosis challenges in the ASEAN region.
Source: Takeda
